文献速递肺外科

早期脓胸:纤溶治疗与胸腔镜剥脱术的成本效果分析

Cost-Effectiveness Analysis of Fibrinolysis vs Thoracoscopic Decortication for Early Empyema.
PubMed 文献 · Ann Thorac Surg · 2020-11-27

本研究通过决策分析模型比较胸腔镜剥脱术与胸腔内纤溶治疗早期脓胸的成本效果。基础病例为65岁男性,纤溶治疗成本略高(13965美元 vs 13345美元)但1年健康效用更高(0.80 vs 0.71),故更具成本效果。敏感性分析显示纤溶成功率>60%或初始成本<13000美元时纤溶更优。

要点

  • 纤溶治疗1年健康效用0.80,高于胸腔镜剥脱术的0.71
  • 胸腔镜剥脱术成本13345美元,低于纤溶治疗的13965美元
  • 纤溶成功率>60%或初始成本<13000美元时纤溶更具成本效果

核心结论

  • 对于可耐受两种治疗的早期脓胸患者,胸腔镜剥脱术与胸腔内纤溶治疗的成本效果几乎相当。

研究设计与样本

  • 决策分析模型,基础病例为65岁早期脓胸男性,比较胸腔镜剥脱术与胸腔内组织型纤溶酶原激活剂联合脱氧核糖核酸酶治疗。

主要发现

  • 胸腔镜剥脱术成本13345美元,纤溶治疗成本13965美元。
  • 纤溶治疗1年健康效用为0.80,胸腔镜剥脱术为0.71。
  • 基础病例中纤溶治疗更具成本效果。

关键数值与推荐

  • 纤溶治疗作为初始治疗更具成本效果的条件:成功率>60%或初始成本<13000美元。
  • 成功治疗定义为影像学上脓胸完全或接近完全吸收。
  • 效果定义为脓胸后1年健康效用。

临床怎么用

  • 对于可耐受两种治疗的早期脓胸患者,选择初始治疗时应综合考虑患者特异性因素以及两种方案的成本和效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical decortication is recommended by national guidelines for management of early empyema, but intrapleural fibrinolysis is frequently used as a first-line therapy in clinical practice. This study compared the cost-effectiveness of video-assisted thoracoscopic surgery (VATS) decortication with intrapleural fibrinolysis for early empyema. METHODS: A decision analysis model was developed. The base clinical case was a 65-year-old man with early empyema treated either by VATS decortication or intrapleural tissue plasminogen activator and deoxyribonuclease. The likelihood of key outcomes occurring was derived from the literature. Medicare diagnosis-related groups and manufacturers' drug prices were used for cost estimates. Successful treatment was defined as complete or nearly complete resolution of empyema on imaging. Effectiveness was defined as health utility 1 year after empyema. RESULTS: Intrapleural tissue plasminogen activator and deoxyribonuclease were more cost-effective than VATS decortication for treating early empyema for the base clinical case. Surgical decortication had a slightly lower cost than fibrinolysis ($13,345 vs $13,965), but fibrinolysis had marginally higher effectiveness at 1 year (health utility of 0.80 vs 0.71). Therefore, fibrinolysis was the more cost-effective option. Sensitivity analyses found that fibrinolysis as the initial therapy was more cost-effective when the probability of success was greater than 60% or the initial cost was less than $13,000. CONCLUSIONS: Surgical decortication and intrapleural fibrinolysis have nearly equivalent cost-effectiveness for early empyema in patients who can tolerate both procedures. Surgeons should consider patient-specific factors, as well as the cost and effectiveness of both modalities, when deciding on an initial treatment for early empyema.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Shipe ME, Maiga AW, Deppen SA, et al. Cost-Effectiveness Analysis of Fibrinolysis vs Thoracoscopic Decortication for Early Empyema. Ann Thorac Surg. 2020. PMID: 33253674. doi:10.1016/j.athoracsur.2020.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。